AcelaBio
Private Company
Funding information not available
Overview
AcelaBio is a specialized CRO founded in 2016, focusing on advanced histopathology and spatial biology services to accelerate biomarker development in clinical trials. Its core offering integrates a wet lab for tissue processing and staining with a dry lab for AI-powered digital image and bioinformatics analysis, creating a seamless 'sample to score' workflow. The company is positioned in the high-growth precision medicine and spatial biology markets, serving as a critical partner for drug developers needing complex tissue-based data. As a private, revenue-generating services firm, its success is tied to the broader adoption of biomarker-driven drug development and spatial transcriptomics technologies.
Technology Platform
Integrated 'sample-to-score' platform combining a CAP-accredited wet lab for tissue processing, staining (IHC, ISH), and spatial transcriptomics (10X Genomics Visium) with a dry lab for AI-powered digital image analysis, custom algorithm development, and bioinformatics.
Opportunities
Risk Factors
Competitive Landscape
AcelaBio competes with large, full-service CROs that have pathology divisions (e.g., Labcorp, IQVIA) and other specialized pathology/digital pathology CROs (e.g., Flagship Biosciences, Reveal Biosciences). Its differentiation lies in its deep vertical integration, focused spatial transcriptomics offering, and strong emphasis on pathological oversight within a service model.